Structure-activity relationships of cyclic enediyned related to dynemicin A-II. Synthesis and antitumor activity of 9- and 12-substituted enediynes equipped with aryl carbamate moietes

Bioorganic and Medicinal Chemistry

Volumn 5, Issue 5, 1997, Pages 903-919

  Unno, Ryoichi ^a   Michishita, Hisashi ^a   Inagaki, Hideaki ^a   Suzuki, Yoko ^a   Baba, Yutaka ^a   Jomori, Takahito ^a   Moku, Masatoshi ^b   Nishikawa, Toshio ^b   Isobe, Minoru ^b  

^a SANWA KAGAKU KENKYUSHO CO LTD   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DYNEMICIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DRUG ACTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LEUKEMIA P 388; MOUSE; NONHUMAN; SQUAMOUS CELL CARCINOMA; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTHRAQUINONES; ANTIBIOTICS, ANTINEOPLASTIC; CELL DEATH; CELL LINE; DNA; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; ENEDIYNES; LEUKEMIA P388; MICE; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 0030926534     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(97)00027-8     Document Type: Article

References (54)

1. Unno, R.; Michishita, H.; Inagaki, H.; Suzuki, Y.; Baba, Y.; Jomori, T.; Nishikawa, T.; Isobe, M. Bioorg. Med. Chem., preceding paper in this series.
2. (a) Nishikawa, T.; Ino, A.; Isobe, M.; Goto, T. Chem. Lett. 1991, 1271.
3. (b) Isobe, M.; Nishikawa, T.; Yamamoto, N.; Tsukiyama, T.; Ino, A.; Okita, T. J Heterocycl. Chem. 1992, 29, 619.
4. (c) Nishikawa, T.; Ino, A.; Isobe, M. Tetrahedron 1994, 50, 1449.
5. (d) Nishikawa, T.; Shibuya, S.; Isobe, M. Synlett 1994, 482.
6. (e) Nishikawa, T.; Yoshikai, M.; Obi, K.; Kawai, T.; Unno, R.; Jomori, T.; Isobe, M. Tetrahedron 1995, 51, 9339.
7. (f) Unno, R.; Michishita, H.; Inagaki, H.; Baba, Y.; Jomori, T.; Nishikawa, T.; Isobe, M. Chem. Pharm. Bull. 1997, 45, 125.
8. (a) Wender, P. A.; Zercher, C. K. J. Am. Chem. Soc. 1991, 113, 2311.
9. (b) Wender, P. A.; Zercher, C. K.; Beckham, S.; Haubold, E. J. Org. Chem. 1993, 58, 5867.
10. (c) Wender, P. A.; Beckham, S.; O'Leary, J. G. Synthesis 1994, 1278.
11. (d) Wender, P. A.; Beckham, S.; Mohler, D. L. Tetrahedron Lett. 1995, 36, 209.
12. Kende, A. S.; Smith, C. A. Tetrahedron Lett. 1988, 29, 4217.
13. Danishefsky, S. J.; Mantlo, N. B.; Yamashita, D. S. J. Am. Chem. Soc. 1988, 110, 6890.
14. (a) Boekelheide, B. V.; Linn, W. J. J. Am. Chem. Soc. 1954, 76, 1286.
15. (b) Nicolaou, K. C.; Hwang, C.-K.; Smith, A. L.; Wendeborn, S. V. J. Am. Chem. Soc. 1990, 112, 7416.
16. Knoll, A.-G. Ger. Patent 880444 1953 [Chem. Abstr., 1954, 52, 11127h].
17. Sonogashira, K.; Tohda, Y.; Hagihara, N. Tetrahedron Lett. 1975, 4467.
18. (a) Imamoto, T.; Sugiura, Y.; Takiyama, N. Tetrahedron Lett. 1984, 25, 4233.
19. (b) For the application to synthesis of neocarzinostatin chromophore analogue, see: Myers, A. G.; Harrington, P. M.; Kuo, E. Y. J. Am. Chem. Soc. 1991, 113, 694.
20. (c) For the application to synthesis of dynemicin A analogue, see: Nishikawa, T.; Isobe, M.; Goto, T. Synlett 1991, 393.
21. (d) For the application to synthesis of kedarcidin chromophore analogue, see: Iida, K.; Hirama, M. J. Am. Chem. Soc. 1994, 116, 10310.
22. (a) Dess, D. B.; Martin, J. C. J. Am. Chem. Soc. 1991, 113, 7277.
23. (b) Ireland, R. E.; Liu, L. J. Org. Chem. 1993, 55, 2899.
24. For the deoxygenation of dynemicin A analogues, see: (a) Nicolaou, K. C.; Smith, A .L.; Wendeborn, S. V.; Hwang, C.-K. J. Am. Chem. Soc. 1991, 113, 3106.
25. (b) Ref. 6b.
26. Nozaki, K.; Oshima, K.; Utimoto, K. Tetrahedron Lett. 1988, 29, 6125.
27. The (9S*)-isomer and (9R*)-isomer represent the (2R*,9S*,10S*,16R*)-(±)-isomer and (2R*,9R*,10S*,16R*)-(±)-isomer, respectively.
28. (a) Jones, R. R.; Bergman, R. G. J. Am. Chem. Soc. 1972, 94, 660.
29. (b) Lockhart, T. P.; Gomita, P. B.; Bergman, R. G. J. Am. Chem. Soc. 1981, 103, 4091.
30. (c) Darby, N.; Kim, C. U.; Salaun, J. A.; Shelton, K. W.; Takada, S.; Masamune, S. J. Chem. Soc. Chem. Commun. 1971, 1516.
31. Myers, A. G.; Dragovich, P. S. J. Am. Chem. Soc. 1992, 114, 5859.
32. The molecular orbital calculations (PM3) were carried out with the quantum chemistry program package MOPAC (QCPE program # 455) version 6.0 (Stewart, J. J. P. J. Comp.-Aided Mol. Design, 1990, 4, 1) running on a graphics workstation Indigo 2 (Silicon Graphics). The calculated cd distance of dynemicin A is 3.48Å.
33. For the correlation between cd distance and reactivity of Bergman cycloaromatization, see: (a) Nicolaou, K. C.; Zuccarello, G.; Ogawa, Y.; Schweiger, E. J.; Kumazawa, T. J. Am. Chem. Soc. 1988, 110, 4866.
34. (b) Nicolaou, K. C.; Zuccarello, G.; Reimer, C.; Estevez, V. A.; Dai, W.-M. J. Am. Chem. Soc. 1992, 114, 7360.
35. For the DNA cleavage studies on dynemicin A analogues, see: (a) Nicolaou, K. C.; Dai, W.-M.; Tsay, S.-C.; Estevez, V. A.; Wrasidlo, W. Science 1992, 256, 1172.
36. (b) Nicolaou, K. C.; Dai, W.-M; Tsay, S.-C.; Wrasidlo, W. Bioorg. Med. Chem. Lett. 1992, 2, 1155.
37. (c) Wender, P. A.; Zercher, C. K.; Beckham, S.; Haubold, E. J. Org. Chem. 1993, 58, 5867.
38. (d) Shair, M. D.; Yoon, T. Y.; Chou, D.; Danishefsky, S. J. Angew. Chem. Int. Ed. Engl. 1994, 33, 2477.
39. (e) Myers, A. G.; Cohen, S. B.; Tom, N. J.; Madar, D. J.; Fraley, M. E. J. Am. Chem. Soc. 1995, 117, 7574.
40. (f) Refs 2c, 2e, and 2f.
41. For the studies on the in vitro cytotoxicity of dynemicin A analogues, see: (a) Magnus, P.; Eisenbeis, S. A.; Rose, W. C.; Zein, N.; Solomon, W. J. Am. Chem. Soc. 1993, 115, 12627.
42. (b) Hay, M. P.; Wilson, W. R.; Denny, W. A. Bioorg. Med. Chem. Lett. 1995, 5, 2829.
43. (c) Shair, M. D.; Yoon, T. Y.; Mosny, K. K.; Chou, T. C.; Danishefsky, S. J. J. Am. Chem. Soc. 1996, 118, 9509.
44. (d) Refs 2f, 18a, 18b, and 18d.
45. Nicolaou, K. C.; Maligres, P.; Suzuki, T.; Wendborn, S. V.; Dai, W.-M.; Chadha, R. K. J. Am. Chem. Soc. 1992, 114, 8890.
46. (a) Toshima, K.; Ohta, K.; Ohashi, A.; Nakamura, T.; Nakata, M.; Matsumura, S. J. Chem. Soc. Chem. Commun. 1993, 1525.
47. (b) Toshima, K.; Ohta, K.; Ohashi, A.; Nakamura, T.; Nakata, M.; Tatsuta, K.; Matsumura, S. J. Am. Chem. Soc. 1995, 117, 4822.
48. For the studies on the in vivo antitumor activity of dynemicin A analogues, see refs 2f, 18d, 19a, and 19c.
49. For reviews, see: (a) Nicolaou, K. C.; Dai, W.-M. Angew. Chem. Int. Ed. Engl. 1991, 30, 1387.
50. (b) Nicolaou, K. C.; Smith, A. L.; Yue, E. W. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 5881.
51. (c) Grissom, J. W.; Gunawardena, G. U.; Klingberg, D.; Huang, D. Tetrahedron 1996, 52, 6453.
52. Nicolaou, K. C.; Stabila, P.; Esmaeli-Azad, B.; Wrasidlo, W.; Hiatt, A. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 3142.
53. Zein, N.; Solomon, W.; Casazza, A. M.; Kadow, J. F.; Krishnan, B. S.; Tun, M. M.; Vyas, D. M.; Doyle, T. W. Bioorg. Med. Chem. Lett. 1993, 3, 1351.
54. Ukai, T.; Kawazura, H.; Ishii, Y.; Bonnet, J. J.; Ibers, J. A. J. Organomet. Chem. 1974, 65, 253.